Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has received feedback from the US FDA following its 'end of review' Type A meeting request with respect to the Sofdra new drug application review. …
FDA confirms approach to Sofdra NDA resubmission and the materials required
December 4, 2023 Australian Biotech
Latest Video
New Stories
-
Cabinet documents reveal decades-old focus on faster PBS listings
January 24, 2025 - - Latest News -
No probity advisor but what about a form of confidentiality deed?
January 24, 2025 - - Latest News -
CEPI backing for Vaxxas to advance needle-free thermostable mRNA vaccines
January 23, 2025 - - Latest News -
New preventive treatments could support ongoing fight against COVID
January 23, 2025 - - Latest News -
Pharmac encourages input on on multiple medicines funding proposal
January 22, 2025 - - Latest News -
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech -
Emyria announces key leadership changes
January 22, 2025 - - Latest News